Medartis cancels convertible bond despite sweetening terms

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity
Equity-Linked

Medartis cancels convertible bond despite sweetening terms

Victoria Thiele
April 08, 2022 05:58 pm
A skull with titanium plates of Medartis, a Swiss producer of metal implants for the surgical management of fractures, is seen during a news conference to present the planned IPO, in Zurich, Switzerland March 12, 2018. REUTERS/Moritz Hager

'Aggressive' pricing fails to attract investors

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Equity-LinkedSwitzerlandHealth and Biotech
VT
Victoria Thiele
Senior Reporter - CLOs
Contact
Gift this article